TY - JOUR T1 - Real-world treatment patterns of newly diagnosed patients with asthma and/or COPD JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.PA3520 VL - 58 IS - suppl 65 SP - PA3520 AU - Aniek Markus AU - Peter Rijnbeek AU - Jan Kors AU - Guy Brusselle AU - Edward Burn AU - Daniel Prieto-Alhambra AU - Katia Verhamme Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/PA3520.abstract N2 - Current guidelines provide clinical recommendations for asthma and COPD treatment, but there is a lack of knowledge how these are adhered to. We give insight in treatment patterns of newly diagnosed patients with asthma, COPD and ACO in three electronic data sources from the Netherlands, UK and US.In each data source, mapped to the OMOP-Common Data Model, we created three study cohorts by identifying adult patients with a first diagnosis of asthma, COPD or ACO. Patients needed to have at least 1 year prior to incident diagnosis and 3 year follow-up time.Treatment episodes were defined as subscriptions from the same class with a maximum gap of 30 days. A prescription of another class was considered a switch if it had less than 30 days overlap with the previous class and a combination therapy otherwise. Results were visualized with sunburst plots.We identified a total of 566168 asthma, 115971 COPD and 96985 ACO patients. Approximately one-third of asthma patients start with SABA followed by ICS in Europe and systemic steroid bursts in US. In Europe, COPD patients are starting more often with LAMA than asthma patients. In the US treatment for asthma and COPD are comparable and systemic steroids are frequently used as first treatment. ACO patients most often receive treatment and differences are smaller between US and Europe.We conclude that treatment patterns vary across countries with substantial differences in first treatments.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3520.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -